MN-166 (ibudilast) Publications
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.
N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.
PMID: 30157388
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators.
Neurology. 2010 Mar 30;74(13):1033-40. doi: 10.1212/WNL.0b013e3181d7d651. Epub 2010 Mar 3.
PMID: 20200338
Primary neuroprotection: the Holy Grail of multiple sclerosis therapy.
Fox RJ.
Neurology. 2010 Mar 30;74(13):1018-9. doi: 10.1212/WNL.0b013e3181d6b165. Epub 2010 Mar 3. No abstract available.
PMID: 20200341
Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A.
Neuropharmacology. 2004 Mar;46(3):404-11.
PMID: 14975696
Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons.
Tominaga Y, Nakamura Y, Tsuji K, Shibata T, Kataoka K.
Clin Exp Pharmacol Physiol. 1996 Jun-Jul;23(6-7):519-23.
PMID: 8800577
Phosphodiesterase inhibitors suppress IL-12 production with microglia and T helper 1 development.
Suzumura A, Ito A, Mizuno T.
Mult Scler. 2003 Dec;9(6):574-8.
PMID: 14664469
Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity.
Yoshioka A, Shimizu Y, Hirose G, Kitasato H, Pleasure D.
J Neurochem. 1998 Jun;70(6):2416-23.
PMID: 9603206